Showing 5111-5120 of 8729 results for "".
- Annual Science of Skin Event Highlights Empowering Conversations About Chronic Diseaseshttps://practicaldermatology.com/news/annual-science-skin-event-highlights-empowering-conversations-about-chronic-diseases/2467751/Empowering conversations around chronic skin diseases is something AbbVie aims to normalize. The fourth annual Science of Skin event featured a panel of experts and patients who shared insights on managing chronic skin conditions and improving quality of life, and Practical Dermatology was there.
- Five-Year Study Validates Dupilumab for Atopic Dermatitis Managementhttps://practicaldermatology.com/news/five-year-study-validates-dupilumab-atopic-dermatitis-management/2467714/New research has provided evidence of benefit from a long-term strategy of dupilumab for the treatment of atopic dermatitis (AD). Researchers for the multicenter cohort study looked at clinical effectiveness, response times, and reasons for discontinuation of dupilumab treatment over a pe
- Tildrakizumab Shows Efficacy in Plaque Psoriasishttps://practicaldermatology.com/news/tildrakizumab-shows-significant-efficacy-plaque-psoriasis/2467713/Tildrakizumab was associated with improvements in disease severity in patients with moderate-to-severe plaque psoriasis, according to results from a new study in the Journal of Drugs in Dermatology. Researchers for the phase 4, multicenter, uncontrolled, open-label trial enrolle
- Galderma to Pursue a Scientific Partnership with L’Oréalhttps://practicaldermatology.com/news/galderma-to-pursue-a-scientific-partnership-with-loreal/2467670/Galderma has signed a memorandum of understanding with L’Oréal to work toward a new research and development (R&D) collaboration in the form of a scientific partnership, according to a company news release. The partnership would
- Alopecia Areata Linked to Increased Psychiatric, Autoimmune Conditionshttps://practicaldermatology.com/news/alopecia-areata-linked-increased-psychiatric-autoimmune-conditions/2467632/A new retrospective analysis indicated that patients with newly diagnosed alopecia areata (AA) tended to have higher prevalence of psychiatric and autoimmune comorbidities. Researchers for the study focused on adolescents and adults aged 12-64 years diagnosed with AA (compared to a control
- FDA Approves Deuruxolitinib for Alopecia Areatahttps://practicaldermatology.com/news/fda-approves-deuruxolitinib-alopecia-areata/2467563/The U.S. Food and Drug Administration (FDA) has approved deuruxolitinib 8-mg tablets for the treatment of adults with severe alopecia areata, Sun Pharmaceuticals Industries Limited announced in a press release. Deuroxolitinib is available from Sun Pharma under the name LEQSELVI. "
- Cemiplimab Shows Promising Results in Refractory cSCC Patientshttps://practicaldermatology.com/news/cemiplimab-shows-promising-results-refractory-cscc-patients/2467554/New research suggests cemiplimab is safe and effective in patients with refractory locally advanced (LA) and metastatic cutaneous squamous cell carcinoma (cSCC). Researchers for the retrospective single-center Canadian study sought to characterize the real-world use of cemiplimab in pati
- Study: Crotoxin Demonstrates Efficacy Against Melanoma with Reduced Toxicityhttps://practicaldermatology.com/news/crotoxin-demonstrates-efficacy-against-melanoma-reduced-toxicity/2467490/A new study in Frontiers in Pharmacology indicated that crotoxin (CTX), a component of snake venom, was associated with antiproliferative effects on melanoma cells. "Melanoma, a highly aggressive skin cancer originating in melanocytes, poses a significant threat due to its metast
- Weekly Cendakimab Dosing Effective in Reducing AD Severityhttps://practicaldermatology.com/news/weekly-cendakimab-dosing-effective-reducing-ad-severity/2467489/New research shows that cendakimab is safe and efficacious at certain dosing levels over a 16-week study period in patients with moderate-to-severe atopic dermatitis (AD). The study authors for the phase 2 trial included 221 adult patients with moderate-to-severe AD from the United States
- sNDA Submitted for Roflumilast Foam 0.3% for Scalp and Body Psoriasishttps://practicaldermatology.com/news/snda-submitted-roflumilast-foam-03-scalp-and-body-psoriasis/2467457/A supplemental New Drug Application (sNDA) has been submitted for ZORYVE (roflumilast) foam 0.3%, a once-daily, next-generation phosphodiesterase-4 (PDE4) inhibitor, for the treatment of adults and adolescents ages 12 and over with scalp and body psoriasis, Arcutis Biotherapeutics, Inc., announce